Zydus Lifesciences has been granted a patent for a ready-to-use liquid formulation containing sildenafil citrate, designed for treating conditions like pulmonary arterial hypertension and erectile dysfunction. The formulation includes 10 mg/mL of sildenafil and glycerin as a wetting agent, with specific particle size requirements. GlobalData’s report on Zydus Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of June 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12005062B2 describes a ready-to-use liquid oral formulation containing approximately 10 mg/mL of sildenafil citrate, characterized by a d90 particle size ranging from about 10 to 100 microns. The formulation includes one or more pharmaceutically acceptable excipients, notably a wetting agent, glycerin, present in quantities between 100 to 1,000 mg/mL. The pH of the formulation can vary from about 4 to 8, with specific claims detailing pH values of 4 to 6 and a preferred pH of about 5. Additional excipients may include buffering agents and viscosity modifying agents, with a variety of options specified for each category, ensuring the formulation's stability and effectiveness.
Moreover, the patent outlines methods for treating various conditions such as hypertension, pulmonary hypertension, and erectile dysfunction by administering the described formulation. The formulation is noted for its stability, remaining effective for up to six months under specified storage conditions, with strict limits on individual and total impurities. This patent provides a comprehensive approach to the formulation of sildenafil citrate in liquid form, emphasizing its therapeutic applications and the importance of excipient selection in achieving desired stability and efficacy.
To know more about GlobalData’s detailed insights on Zydus Lifesciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
